These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 20481653)

  • 21. Matrix metalloproteinase inhibitors: applications in oncology.
    Yip D; Ahmad A; Karapetis CS; Hawkins CA; Harper PG
    Invest New Drugs; 1999; 17(4):387-99. PubMed ID: 10759405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases.
    Milner JM; Cawston TE
    Curr Drug Targets Inflamm Allergy; 2005 Jun; 4(3):363-75. PubMed ID: 16101546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments.
    Lin H; Xu P; Huang M
    Future Med Chem; 2022 Jan; 14(1):35-51. PubMed ID: 34779649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
    Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
    Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.
    Hu J; Van den Steen PE; Sang QX; Opdenakker G
    Nat Rev Drug Discov; 2007 Jun; 6(6):480-98. PubMed ID: 17541420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
    Mitsiades N; Poulaki V; Mitsiades CS; Anderson KC
    Expert Opin Investig Drugs; 2001 Jun; 10(6):1075-84. PubMed ID: 11772236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloprotease inhibitors: design from structure.
    Borkakoti N
    Biochem Soc Trans; 2004 Feb; 32(Pt 1):17-20. PubMed ID: 14748704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matrix metalloproteinases. Novel targets for directed cancer therapy.
    Yu AE; Hewitt RE; Connor EW; Stetler-Stevenson WG
    Drugs Aging; 1997 Sep; 11(3):229-44. PubMed ID: 9303281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Matrix metalloproteinase inhibitors as anticancer agents.
    Konstantinopoulos PA; Karamouzis MV; Papatsoris AG; Papavassiliou AG
    Int J Biochem Cell Biol; 2008; 40(6-7):1156-68. PubMed ID: 18164645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matrix metalloproteinase inhibitors: present achievements and future prospects.
    Denis LJ; Verweij J
    Invest New Drugs; 1997; 15(3):175-85. PubMed ID: 9387040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in the development of MMPIs and APNIs based on the pyrrolidine platforms.
    Li X; Li J
    Mini Rev Med Chem; 2010 Aug; 10(9):794-805. PubMed ID: 20482497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
    Li W; Saji S; Sato F; Noda M; Toi M
    Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxamic acids as matrix metalloproteinase inhibitors.
    Verma RP
    Exp Suppl; 2012; 103():137-76. PubMed ID: 22642192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies.
    Rao BG
    Curr Pharm Des; 2005; 11(3):295-322. PubMed ID: 15723627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases.
    Castro MM; Kandasamy AD; Youssef N; Schulz R
    Pharmacol Res; 2011 Dec; 64(6):551-60. PubMed ID: 21689755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors?
    Corbitt CA; Lin J; Lindsey ML
    Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):135-42. PubMed ID: 18221058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
    Yang JS; Lin CW; Su SC; Yang SF
    Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is there new hope for therapeutic matrix metalloproteinase inhibition?
    Vandenbroucke RE; Libert C
    Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
    Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.
    Overall CM; Kleifeld O
    Nat Rev Cancer; 2006 Mar; 6(3):227-39. PubMed ID: 16498445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.